接受高剂量利福平的结核合并人类免疫缺陷病毒患者中多替拉韦与依非韦伦浓度下降而病毒学抑制维持
一项随机开放标签试验将新诊断结核患者随机分配至高剂量(35 mg/kg)或标准剂量(10 mg/kg)每日利福平,未接受抗逆转录病毒治疗者随机分配至以多替拉韦或依非韦伦为基础的方案。第6周采血测浓度:高剂量较标准剂量利福平的多替拉韦谷浓度几何均值比为0.57(95%CI 0.34-0.97,P=0.039),依非韦伦中位浓度几何均值比为0.63(95%CI 0.38-1.07,P=0.083)。第24周HIV治疗失败率与药物相关3-4级不良事件发生率在两利福平剂量间相似,高剂量利福平耐受良好并与痰培养转阴更快的趋势相关。
要点
- 高剂量较标准剂量利福平使多替拉韦谷浓度几何均值比为0.57(95%CI 0.34-0.97,P=0.039)。
- 高剂量较标准剂量利福平的依非韦伦中位浓度几何均值比为0.63(95%CI 0.38-1.07,P=0.083)。
- 两利福平剂量间第24周HIV治疗失败率与药物相关3-4级不良事件发生率相似。
核心结论
- 与标准剂量利福平相比,高剂量利福平降低多替拉韦和依非韦伦暴露,但各治疗组HIV抑制相似。
- 高剂量利福平在HIV感染者中耐受良好,并与痰培养转阴更快的趋势相关。
研究设计与样本
- 随机、开放标签试验,新诊断结核患者随机接受高剂量(35 mg/kg)或标准剂量(10 mg/kg)每日利福平。
- 未接受抗逆转录病毒治疗的患者随机接受以多替拉韦或依非韦伦为基础的抗逆转录病毒治疗。
- 共128例患者随机分组,中位CD4计数为191 cells/mm3。
- 第6周检测多替拉韦谷浓度或依非韦伦中位浓度,第24周检测HIV病毒载量。
主要发现
- 高剂量较标准剂量利福平的多替拉韦谷浓度几何均值比为0.57(95%CI 0.34-0.97,P=0.039)。
- 高剂量较标准剂量利福平的依非韦伦中位浓度几何均值比为0.63(95%CI 0.38-1.07,P=0.083)。
- 两利福平剂量间达到多替拉韦谷浓度或依非韦伦中位浓度目标的比例无显著差异。
- 第24周HIV治疗失败发生率在两利福平剂量间相似(14.9% vs 14.0%,P=0.901)。
- 药物相关3-4级不良事件发生率在两利福平剂量间相似(9.8% vs 6%)。
关键数值与推荐
- 多替拉韦谷浓度几何均值比0.57(95%CI 0.34-0.97,P=0.039),比较高剂量与标准剂量利福平。
- 依非韦伦中位浓度几何均值比0.63(95%CI 0.38-1.07,P=0.083),比较高剂量与标准剂量利福平。
- 第24周HIV治疗失败:高剂量利福平组14.9% vs 标准剂量利福平组14.0%(P=0.901)。
- 药物相关3-4级不良事件:高剂量利福平组9.8% vs 标准剂量利福平组6%。
- 第8周痰培养仍阳性:高剂量利福平组18.6% vs 标准剂量利福平组37.0%(P=0.063)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Higher doses of rifampicin may improve treatment outcomes and reduce the duration of tuberculosis (TB) therapy. However, drug-drug interactions with antiretroviral therapy (ART) and safety in people with human immunodeficiency virus (HIV) have not been evaluated. METHODS: This was a randomized, open-label trial where newly diagnosed TB patients were randomized to higher (35 mg/kg) or standard (10 mg/kg) daily-dose rifampicin. ART treatment-naive patients were randomized to dolutegravir- or efavirenz-based ART. At week 6, trough dolutegravir or mid-dose efavirenz plasma concentrations were assayed. HIV viral load was measured at week 24. RESULTS: Among 128 patients randomized, the median CD4 count was 191 cells/mm3. The geometric mean ratio (GMR) for trough dolutegravir concentrations on higher- vs standard-dose rifampicin was 0.57 (95% confidence interval [CI], .34-.97; P = .039) and the GMR for mid-dose efavirenz was 0.63 (95% CI, .38-1.07; P = .083). There was no significant difference in attainment of targets for dolutegravir trough or efavirenz mid-dose concentrations between rifampicin doses. The incidence of HIV treatment failure at week 24 was similar between rifampicin doses (14.9% vs 14.0%, P = .901), as was the incidence of drug-related grade 3-4 adverse events (9.8% vs 6%). At week 8, fewer patients remained sputum culture positive on higher-dose rifampicin (18.6% vs 37.0%, P = .063). CONCLUSIONS: Compared with standard-dose rifampicin, high-dose rifampicin reduced dolutegravir and efavirenz exposures, but HIV suppression was similar across treatment arms. Higher-dose rifampicin was well tolerated among people with HIV and associated with a trend toward faster sputum culture conversion. CLINICAL TRIALS REGISTRATION: NCT03982277.
引用
- Sekaggya-Wiltshire C, Nabisere R, Musaazi J, et al. Decreased Dolutegravir and Efavirenz Concentrations With Preserved Virological Suppression in Patients With Tuberculosis and Human Immunodeficiency Virus Receiving High-Dose Rifampicin. Clin Infect Dis. 2023. PMID: 35861296. doi:10.1093/cid/ciac585
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。